VivoSeq
Other

Tocilizumab

0

Pipeline Programs↗

9

Active Trials↗

2

Companies Involved↗

Tocilizumab is an early-stage landscape with 0 programs across 2 companies. The most active players are Roche, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

40

clinical trials

Completed20 · 50%
Unknown status8 · 20%
Recruiting5 · 13%
Not yet recruiting2 · 5%
Active, not recruiting2 · 5%
Terminated1 · 3%
Other2 · 5%

Clinical Trials

Trial Activity

40 trials

RCT of Tocilizumab for Anti-MDA5+DM
Recruiting·PPeking Union Medical College Hospital·N/A·NCT07377058·110 enrolled
Use of Tocilizumab Drug Levels to Optimize Treatment in RA
Recruiting·—·Phase 4·NCT03895879·98 enrolled
PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT06430736·100 enrolled
Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
Recruiting·SShahid Beheshti University of Medical Sciences·N/A·NCT07006532·50 enrolled
Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05845723·81 enrolled
A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers
Active, not recruiting·AAO GENERIUM·Phase 1·NCT06488521·256 enrolled
Tocilizumab in Children With ACP
Active, not recruiting·UUniversity of Colorado, Denver·Phase 1·NCT03970226·9 enrolled
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
Not yet recruiting·YYale University·Phase 3·NCT07281027·438 enrolled
Tocilizumab in Chronic Inflammatory CPPD Disease
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT07254637·80 enrolled
Tocilizumab Real-Life Human Factors (RLHFs) Validation Study
Completed·Roche logoRoche·Phase 4·NCT02682823·91 enrolled
A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy Volunteers
Completed·AAO GENERIUM·Phase 1·NCT06481202·43 enrolled
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
Completed·Roche logoRoche·Phase 3·NCT00720798·2,067 enrolled
A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers
Completed·Roche logoRoche·Phase 4·NCT01991990·18 enrolled
Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year
Completed·Roche logoRoche·N/A·NCT02608112·291 enrolled
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04331808·228 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)